An evidence-based estimate of the global point prevalence is important to attract attention from the policy maker. Rare diseases (RDs) are numerous, heterogeneous in nature, and geographically disparate. Few are preventable or curable, most are chronic and many result in early death. By indicating the number of prevalence of rare diseases, it would provide evidence for designing regional, national, and global strategies. These would directly benefit the vast majority of patients with the most prevalent RDs and create the necessary framework of expertise to serve patients with the rarest such diseases.
Read more here about, Estimating Cumulative Point Prevalence of Rare Diseases: Analysis of the Orphanet Database